From C&C website:
Yesterday, BioSpace ran a pharma-insider article headlined, “
Moderna’s RSV Vaccines Run Into Safety Roadblock.” Corporate media has hysterical blindless and can’t see this story. The sub-headline added, “The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with Moderna’s investigational mRNA vaccines.” In other words, the vaccine didn’t work (ineffective) and made the infants
more susceptible to RSV (unsafe).
Yesterday, in an FDA briefing document released before a vaccine safety meeting late this week, the agency revealed
severe side effects in two of Moderna’s mRNA candidates for infant immunization for RSV.
The report said that in vaccinated study participants aged 8 months to less than 24 months, there was at least one severe or very severe RSV infection. In the even younger group—5 to 8 months—there were
five serious RSV infections, with one patient requiring mechanical ventilation.
The trial is now paused pending a safety investigation (conducted by Moderna, of course).
First off, this news will not be well received by investors, who’ve already been fleeing the stock during most of 2024. The RSV ‘vaccine’ is Moderna’s most promising pipeline product. The company’s stock, which once traded near $300 a share, now loiters around $42.
Second, and perhaps better, it appears somebody has jump-started the FDA’s vaccine advisory committee. It is up and running again, doing its job, after four years of Nigerian river blindness regarding mRNA safety signals in the covid vaccines.